BR0017319A - Vbeta-dbeta-jbeta t-cell receptor sequence and methods for its detection - Google Patents

Vbeta-dbeta-jbeta t-cell receptor sequence and methods for its detection

Info

Publication number
BR0017319A
BR0017319A BR0017319-3A BR0017319A BR0017319A BR 0017319 A BR0017319 A BR 0017319A BR 0017319 A BR0017319 A BR 0017319A BR 0017319 A BR0017319 A BR 0017319A
Authority
BR
Brazil
Prior art keywords
oligonucleotide
methods
sequence
jbeta
dbeta
Prior art date
Application number
BR0017319-3A
Other languages
Portuguese (pt)
Inventor
Jingwu Z Zhang
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of BR0017319A publication Critical patent/BR0017319A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)

Abstract

"SEQœêNCIA VBETA-DBETA-JBETA RECEPTORA DE CéLULAS T E MéTODOS PARA SUA DETECçãO". Em uma modalidade, a presente invenção é dirigida a um primeiro oligonucleotídeo compreendendo a seq³ência de ou derivada de 5'-CTAGGGCGGGCGGGACTCACCTAC-3' ou a seq³ência de ácido nucléico complementar a mesma. O primeiro oligonucleotídeo pode ser usado com um ácido nucléico de entre 15 e 30 nucleotídeos que não compreende a seq³ência do primeiro oligonucleotídeo e é encontrado na região de VP a JP do gene V<225>13.1 em células T V<225>13.1, em que as seq³ências do oligonucleotídeo e do ácido nucléico não são encontradas no mesmo filamento do par do gene V<225>13.1, para amplificar uma parte do gene V<225>13.1. Alternativamente, o primeiro oligonucleotídeo pode ser usado com uma porção de rotulação em métodos de detecção de um motivo LGRAGLTY encontrado em receptores de células T em células TV<225>13.1. Esse motivo está associado a doenças auto-imunes, tal como esclerose múltipla (MS). Uma vez que o motivo é detectado, a doença auto-imune pode ser tratada ou sua progressão monitorada. A doença auto-imune pode ser tratada através de administração de um ou mais peptídeos compreendendo o motivo LGRAGLTY."T-CELL RECEIVER VBETA-DBETA-JBETA SEQUENCE AND METHODS FOR ITS DETECTION". In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the VP to JP region of the V<225>13.1 gene in V<225>13.1 T cells, where the oligonucleotide and nucleic acid sequences are not found on the same strand of the V<225>13.1 gene pair, to amplify a part of the V<225>13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting an LGRAGLTY motif found on T cell receptors on TV<225>13.1 cells. This motif is associated with autoimmune diseases such as multiple sclerosis (MS). Once the reason is detected, the autoimmune disease can be treated or its progression monitored. The autoimmune disease can be treated by administering one or more peptides comprising the LGRAGLTY motif.

BR0017319-3A 2000-08-22 2000-08-22 Vbeta-dbeta-jbeta t-cell receptor sequence and methods for its detection BR0017319A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/022988 WO2002016434A1 (en) 2000-08-22 2000-08-22 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION

Publications (1)

Publication Number Publication Date
BR0017319A true BR0017319A (en) 2004-01-13

Family

ID=21741700

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017319-3A BR0017319A (en) 2000-08-22 2000-08-22 Vbeta-dbeta-jbeta t-cell receptor sequence and methods for its detection

Country Status (12)

Country Link
EP (1) EP1311543A1 (en)
JP (1) JP2004506743A (en)
KR (1) KR20030086983A (en)
CN (1) CN1505640A (en)
AU (1) AU2000269239A1 (en)
BR (1) BR0017319A (en)
CA (1) CA2420283A1 (en)
HU (1) HUP0400499A2 (en)
IL (2) IL154544A0 (en)
MX (1) MXPA03001569A (en)
PL (1) PL364914A1 (en)
WO (1) WO2002016434A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658926B2 (en) 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
BRPI0305769A8 (en) 2002-08-08 2017-09-12 Baylor College Medicine ISOLATION AND IDENTIFICATION OF T CELLS
AU2003902299A0 (en) * 2003-05-13 2003-05-29 Flinders Medical Centre A method of analysing a marker nucleic acid molecule
WO2008131599A1 (en) * 2007-04-30 2008-11-06 Maxx Genetech Co., Ltd. T-cell receptor vaccines materials and methods
CN102875666B (en) * 2012-09-05 2014-07-09 南方医科大学 Tuberculosis antigen specificity TCR (T cell receptor), recombinant retroviral vector thereof and application
CN102875667B (en) * 2012-09-05 2014-07-09 南方医科大学 HIV-1 (human immunodeficiency virus-1) peptide Env120-128 specificity TCR (T cell receptor), recombinant retroviral vector thereof and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0008966A (en) * 1999-02-23 2002-10-15 Baylor College Medicine T cell receptor vbeta-dbeta-jbeta sequence and processes for its detection

Also Published As

Publication number Publication date
WO2002016434A1 (en) 2002-02-28
AU2000269239A1 (en) 2002-03-04
EP1311543A1 (en) 2003-05-21
HUP0400499A2 (en) 2004-06-28
IL154544A0 (en) 2003-09-17
IL154544A (en) 2010-05-31
JP2004506743A (en) 2004-03-04
PL364914A1 (en) 2004-12-27
CA2420283A1 (en) 2002-02-28
MXPA03001569A (en) 2004-12-13
CN1505640A (en) 2004-06-16
WO2002016434A9 (en) 2003-10-09
KR20030086983A (en) 2003-11-12

Similar Documents

Publication Publication Date Title
BR0008966A (en) T cell receptor vbeta-dbeta-jbeta sequence and processes for its detection
Brooks X chromosome inactivation and autoimmunity
Cortázar et al. The enigmatic thymine DNA glycosylase
O'Connor et al. Ring-opened 7-methylguanine residues in DNA are a block to in vitro DNA synthesis
Nobrega et al. Assembly of the mitochondrial membrane system. DNA sequence and organization of the cytochrome b gene in Saccharomyces cerevisiae D273-10B.
US20180236044A1 (en) Methods and compositions for rna-guided treatment of hiv infection
Crothers et al. Is there a discriminator site in transfer RNA?
Lavollay et al. The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L, D-transpeptidases
Stojković et al. cfr (B), cfr (C), and a new cfr-like gene, cfr (E), in Clostridium difficile strains recovered across Latin America
ES2385867T1 (en) Method and kit for molecular chromosomal quantification
Chmielewicz et al. Detection and multigenic characterization of a novel gammaherpesvirus in goats
Kovalev et al. Natural hybridization of the ticks Ixodes persulcatus and Ixodes pavlovskyi in their sympatric populations in Western Siberia
Weiss et al. Early Epstein-Barr virus genomic diversity and convergence toward the B95. 8 genome in primary infection
Pombert et al. The Ordospora colligata genome: evolution of extreme reduction in microsporidia and host-to-parasite horizontal gene transfer
KR960704033A (en) Oligonucleotides with Activity against Humand Immunodeficiency Virus
BR0005804A (en) Nucleotide sequences encoding genezwa1
Qi et al. Nonstructural protein 4 of porcine reproductive and respiratory syndrome virus modulates cell surface swine leukocyte antigen class I expression by downregulating β2-microglobulin transcription
BR0017319A (en) Vbeta-dbeta-jbeta t-cell receptor sequence and methods for its detection
Whittock et al. Dystrophin point mutation screening using a multiplexed protein truncation test
HUP9702251A2 (en) Multifunctional ligand system for cell-specific transfer of nucleic acid
Guilherme et al. Terminal 18q deletions are stabilized by neotelomeres
WO2018048194A1 (en) Composition and method for improving sensitivity and specificity of detection of nucleic acids using dcas9 protein and grna binding to target nucleic acid sequence
Sojane et al. Individuals with HIV-1 subtype C infection and cryptococcal meningitis exhibit viral genetic intermixing of HIV-1 between plasma and cerebrospinal fluid and a high prevalence of CXCR4-using variants
Seong et al. A single amino acid variation of NV protein of viral hemorrhagic septicemia virus increases protein stability and decreases immune gene expression
Santos-Rebouças Epigenetics of X-chromosome Inactivation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A ?6A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1942 DE 25 - 03 - 2008.